Beyond Air, Inc. Receives Market Authorization for LungFit® PH in Australia
GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) —
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company, has made a significant stride in improving patient care with the market authorization of LungFit® PH by the Australian Therapeutic Goods Administration (TGA). This Class IIb medical device is designed to deliver nitric oxide, a vasodilator, into the inspiratory limb of a patient’s ventilator breathing circuit in a controlled and constant manner throughout the breathing cycle.
What is Nitric Oxide and How Does it Help Patients?
Nitric oxide (NO) is a vital molecule in the human body that plays a key role in various physiological functions, including the regulation of blood flow and oxygen delivery. In medical settings, NO has been used as a therapeutic agent due to its ability to dilate blood vessels and improve oxygenation.
The LungFit® PH device enables healthcare providers to deliver NO directly to patients on ventilators, ensuring a consistent concentration of the gas with each breath. This targeted delivery mechanism can help improve oxygenation and reduce the strain on the heart, particularly in patients with respiratory conditions such as pulmonary hypertension.
Impact on Patients
For patients requiring mechanical ventilation, the availability of LungFit® PH in Australia represents a promising advancement in critical care management. By optimizing oxygen delivery and blood flow, the device has the potential to enhance patient outcomes and quality of life, particularly for those with pulmonary complications.
Impact on the World
Beyond Air’s market authorization of LungFit® PH in Australia marks a significant milestone in the global healthcare landscape. The widespread adoption of NO therapy using innovative devices like LungFit® PH could revolutionize the treatment of respiratory conditions and enhance clinical practices worldwide. As more countries recognize the benefits of NO therapy, we may see broader accessibility to advanced medical technologies that improve patient care and outcomes.
Conclusion:
In conclusion, Beyond Air’s achievement in obtaining market authorization for LungFit® PH in Australia signifies a significant step forward in advancing healthcare innovation and improving patient care. The potential impact of NO therapy on patients and the healthcare industry at large is promising, paving the way for enhanced treatment options and better clinical outcomes globally.
